Economist Ulf Staginnus shared his thoughts on future trends for market access and drug pricing in a recent discussion with The Evidence Base.
“In this interview, Ulf Staginnus (Blueprint Medicines, MA, USA) discusses the impact of real-world evidence (RWE) on pricing and market access, alongside the needs of stakeholders. ” Read more here.
(Source: Ulf Staginnus, The Evidence Base, 11/5/21)
